


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>FEB 11 2011</u> (use as many sheets as necessary)		Complete if Known	
Sheet	1	of	1
		Application Number	10/596,429
		Filing Date	12/17/2004
		First Named Inventor	Norihiro NISHIMOTO
		Art Unit	1647
		Examiner Name	Lorraine Spector
		Attorney Docket Number	053466-0417



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	G1	2005/0158317 A1	07/21/2005	Blay et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	G2	JP 08-311098 A	11/26/996	Daicel Chem. Ind. Ltd. et al.		A
	G3	WO 03/048205 A2	06/12/2003	Universite Claude Bernard Lyon		A✓

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	G4	Office Action dated January 13, 2011, in corresponding Mexican application No. PA/a/2006/005875, 2 pages.	
	G5	KATSUME et al., "Anti-Interleukin 6 (IL-6) Receptor Antibody Suppresses Castleman's Disease Like Symptoms Emerged in IL-6 Transgenic Mice," Cytokine, December 21, 2002, 20(6):304-311.	
	G6	TSUNENARI et al., "Therapeutic Potential of Humanized Anti-interleukin-6 Receptor Antibody: Antitumor Activity in Xenograft Model of Multiple Myeloma," Anticancer Research, 1996, 16:2537-2544.	
	G7	NISHIMOTO et al., "Anti-interleukin 6 receptor antibody treatment in rheumatic disease," Ann. Rheum. Dis., 2000, 59(Suppl 1):i21-i27.	
	G8	MIHARA et al., "IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F ₁ mice," Clin. Exp. Immunol., 1998, 112:397-402.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.S./

Examiner Signature	/Lorraine Spector/	Date Considered	05/16/2011
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.